COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,676 Articles (22,913 medRxiv, 8,763 bioRxiv)

Most recent first Previous |  Page 1039: Articles 10381-10390  | Next

Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients - A Systematic Review
Freilich, D., Victory, J., Gadomski, A.
10.1101/2022.01.11.22269069 — Posted: 2022-01-14
Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant
Hay, J. A., Kissler, S. M., Fauver, J. R., Mack, C., Tai, C. G., Samant, R. M., Connelly, S., Anderson, D. J., Khullar, G., MacKay, M., Patel, M., Kelly, S., Manhertz, A., Eiter, I., Salgado, D., Baker, T., Howard, B., Dudley, J. T., Mason, C. E., Ho, D. D., Grubaugh, N. D., Grad, Y. H.
10.1101/2022.01.13.22269257 — Posted: 2022-01-14
Post-traumatic stress symptoms in cancer patients during the COVID-19 pandemic: a one-year longitudinal study
Bastien, E., Lefevre-Arbogast, S., Lequesne, J., Gernier, F., Cherifi, F., Rigal, O., Guittet, L., Grellard, J.-M., Binarelli, G., Lange, M., Fernette, M., Tron, L., Morel, A., Richard, D., Griffon, B., Leconte, A., Quilan, F., Pepin, L.-F., Jardin, F., Leheurteur, M., Faveyrial, A., Clarisse, B., Joly, F.
10.1101/2022.01.11.22269053 — Posted: 2022-01-13
People with HIV Have Higher Risk of COVID-19 Diagnosis but Similar Outcomes than the General Population
Tang, M. E., Gaufin, T., Anson, R., Zhu, W., Mathews, W. C., Cachay, E. R.
10.1101/2022.01.13.22269178 — Posted: 2022-01-13
The SARS-CoV-2 Omicron (B.1.1.529) variant exhibits altered pathogenicity, transmissibility, and fitness in the golden Syrian hamster model
Yuan, S., Ye, Z.-W., Liang, R., Tang, K., Zhang, A. J., Lu, G., Ong, C. P., Poon, V. K.-M., Chan, C. C.-S., Mok, B. W. Y., Qin, Z., Xie, Y., Sun, H., Tsang, J. O.-L., Yuen, T. T.-T., Chik, K. K.-H., Chan, C. C.-Y., Cai, J.-P., Luo, C., Lu, L., Yip, C. C.-Y., Chu, H., To, K. K.-W., Chen, H., Jin, D.-Y., Yuen, K.-Y., Chan, J. F. W.
10.1101/2022.01.12.476031 — Posted: 2022-01-13
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants
Banerjee, A., Lew, J., Kroeker, A., Baid, K., Aftanas, P., Nirmalarajah, K., Maguire, F., Kozak, R., McDonald, R., Lang, A., Gerdts, V., Straus, S. E., Gilbert, L., Li, A. X., Mozafarihasjin, M., Walmsley, S., Gingras, A.-C., Wrana, J. L., Mazzulli, T., Colwill, K., McGeer, A. J., Mubareka, S., Falzarano, D.
10.1101/2022.01.13.475409 — Posted: 2022-01-13
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
Suryadevara, N., Shiakolas, A., VanBlargan, L., Binshtein, E., Chen, R., Case, J. B., Kramer, K., Armstrong, E., Myers, L., Trivette, A., Gainza, C., Nargi, R., Selverian, C., Davidson, E., Doranz, B., Diaz, S., Handal, L., Carnahan, R. H., Diamond, M. S., Georgiev, I., Crowe, J. E.
10.1101/2022.01.12.476120 — Posted: 2022-01-13
Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study
Corradini, P., Agrati, C., Apolone, G., Mantovani, A., Giannarelli, D., Marasco, V., Bordoni, V., Sacchi, A., Matusali, G., Salvarani, C., Zinzani, P. L., Mantegazza, R., Tagliavini, F., Lupo Stanghellini, M. T., Ciceri, F., Damian, S., Uccelli, A., Fenoglio, D., Silvestris, N., Baldanti, F., Piaggio, G., Ciliberto, G., Morrone, A., Locatelli, F., Sinno, V., Rescigno, M., Costantini, M., VAX4FRAIL Study Group
10.1101/2022.01.12.22269133 — Posted: 2022-01-13
An ensemble prediction model for COVID-19 mortality risk
Li, J., Li, X., Hutchinson, J., Asad, M., Wang, Y., Wang, E.
10.1101/2022.01.10.22268985 — Posted: 2022-01-13
Immunity in Omicron SARS-CoV-2 breakthrough COVID-19 in vaccinated adults
Kared, H., Wolf, A.-S. F. M., Alirezaylavasani, A., Ravussin, A., Solum, G., Tran, T. T., Lund-Johansen, F., Vaage, J. T., Nissen-Meyer, L. S., Nygaard, U. C., Hungnes, O., Robertson, A. H., Meyer Naess, L., Trogstad, L., Magnus, P., Munthe, L. A., Mjaaland, S.
10.1101/2022.01.13.22269213 — Posted: 2022-01-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).